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Abstract 
Purpose: To investigate the prognostic value of circulating tumor cells (CTCs) and to predict the 
treatment response in a non-small cell lung cancer (NSCLC). 
Methodology: A single-center prospective study involving 93 patients with NSCLC was conducted. 
Blood samples were analyzed for CTC count before and after chemotherapy. Clinical relevance of 
CTCs with patient`s characteristics and treatment response were determined. 
Results: Higher levels of CTCs were associated with severe stage of NSCLC (p = 0.003), tumor 
histology (p = 0.014) and metastases (p = 0.013). Significant difference in CTC count was observed in 
favorable (CTCs < 5) and unfavorable (CTCs ≥ 5) groups. Progression-free survival (PFS) was 5.8 
months (range: 5.32 to 6.43) and 2.2 months (range: 1.85 to 3.01) in the favorable and unfavorable 
groups, respectively (HR: 3.88, 95% CI, p < 0.001). Similarly, overall survival (OS) was 7.3 months 
(95% CI, 6.51 to 7.92) and 3.9 months (95% CI, 1.99 to 5.13), respectively (HR: 4.8, 95% CI, p < 0.001). 
Multivariate regression analysis revealed CTCs as strong predictors of OS and PFS. Significant 
reduction (p < 0.001) in CTC count was also observed after one cycle of chemotherapy. 
Conclusion: Patients with low CTC count live longer and remain progression-free for a longer period of 
time than those with high CTC count. High CTCs can be detected in severe forms of lung cancer and 
can be used as a valid prognostic marker. However, this assertion requires validation in larger 
prospective clinical cohorts. 
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Approximately 1.8 million people globally 
suffered from lung cancer in 2012 with an 
estimated mortality of 1.6 million [1]. Compared 
to USA (15.4 %), lung cancer is a predominant 
type of cancer in China with 21.7 % of males and 
14.3 % of females. The incidence of lung cancer 
has increased by 1.63 % per annum from 1988 
to 2005 in China .The mortality rate of lung 
cancer in China was 30.84 per 100,000 in 2005, 
rising by 465 % over the past 30 years [2]. 
 
Primary lung cancer is generally classified into 
small cell lung cancer (SCLC) and non-small cell 
lung cancer (NSCLC), the latter accounts for 80 - 
85 % of primary lung cancer including squamous 
cell carcinoma, adenocarcinoma, and large cell 
carcinoma. SCLC and NSCLC, named for the 
size of the cancer cells, when seen under a 
microscope. SCLC often starts in the bronchi 
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near the center of the chest, and it tends to 
spread widely through the body fairly early in the 
course of the disease. On the other hand, 
NSCLC is comprised of bigger cells under 
microscope. Sometimes SCLC and NSCLC both 
can exist in one patient termed as Combined 
SC/NSC lung carcinoma [3]. The overall survival 
rate of NSCLC is given in Table 1. 
 
Table 1: Five years survival rate of NSCLC according 
to Lung Cancer Staging project [4] 
 
Stage 5-year survival rate 
IA 58 - 73% 
IB 43 - 58% 
IIA 36 - 46% 
IIB   25 - 36% 
IIIA 19 - 24% 
IIIB 7 - 9% 
IV 2-13% 
 
The high mortality seen in NSCLC is due to the 
presence of distant metastasis. Currently tumor 
histology and stage are used as prognostic 
factors in NSCLC. Sometimes, in patients without 
clinically detectable distant metastasis, distant 
micro metastases frequently develop during 
diagnosis, even undergoing surgery [5].  
Moreover, the lack of pharmacodynamics 
biomarkers has hindered successful drug 
development in lung cancer research. These 
biomarkers report early indication of response or 
otherwise treatment [6]. Therefore, sensitive 
prognostic and predictive markers is urgently 
needed in lung oncology. 
 
Circulating tumor cells (CTCs) are tumor cells 
that shed from primary tumors and circulate 
through blood streams and result in formation of 
metastases. CTCs are rare cells among the 
billions of normal cells. Thirteen methods have 
been described to identify these cells and 
amongst them, Cell Search method which 
enumerates CTCs is the only FDA approved 
method [7].  
 
Prognostic significance of CTCs and changes in 
CTCs number with standard therapy in different 
tumors have been elucidated [8-10]. CTCs have 
also been demonstrated as predictive biomarker 
in patients with small cell lung cancer (SCLC) 
[11]. Only a few reports have been published on 
CTCs in NSCLC [6, 12-15]. There is still paucity 
of data demonstrating prognostic significance of 
CTCs in NSCLC.  
 
Therefore current study was conducted to 




Single center prospective study was conducted 
in the outpatient oncology clinic of third affiliated 
Hospital of Qiqihar Medical University Hospital. 
Inclusion criteria for the current study was 
histologically and cytologically confirmed NSCLC 
patients, patients with either lung cancer stage 
IIIA, IIIB or IV, chemotherapy naïve, patients 
having evaluable and measureable disease, 
WHO performance status (PS): 0 – 2, no active 
concurrent malignancy and patients willing to 
participate in study.  
 
The following category of patients were excluded 
from the study: those having prior palliative 
radiotherapy for primary tumor and metastases > 
5 weeks, history of prior malignancy within 5 
years of study entry, inadequate bone marrow, 
hepatic and renal functions.. Stage of cancer was 
determined by using chest X ray, computed 
tomography (CT) of the chest and abdomen, 
brain magnetic resonance imaging (MRI) and 
positron emission tomography (PET). The study 
methodology is schematically described in Figure 
1. 
 
For CTC analysis, peripheral blood sampling was 
done within seven days before initiation of 
treatment (platinum doublet and single agent 
chemotherapy according to patient need) and 
after one cycle of chemotherapy. CTC count 
before treatment served as the baseline value. 
Standard operating procedures and good clinical 
practices were applied during CTC analysis.  
 
CellSearch method was used for CTC analysis. 
Blood samples were taken and stored in 
CellSave conservative bottle (10 ml) at room 
temperature. All the stored samples were 
processed within 96 hours according to 
manufacturer`s instruction [6, 11]. CTC counting 
was carried out without knowledge of patient`s 
clinical characteristics. CTCs count were blinded 
to physicians treating the patients and 
independently merged with clinical data. 
According to findings by Allard et al [16], CTC 
count of 1 has been considered as a normal in 
healthy donors or patients with benign disease. 
Therefore a CTC count ≥ 2 in 7.5 ml of blood was 
considered in current study.  Ethical approval 
was obtained from the hospital ethical review 
board (Ref. No. QMUHRB/216/2011) of Qiqihar 
Medical University hospital. For the human 
protection in current study guidelines of 
Declaration of Helsinki (7th revision) were 
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According to previous studies evaluating 
prognostic significance of CTCs in different types 
of cancers, patients were categorized into 
“favorable” and “unfavorable” groups based upon 
baseline CTC count. Assuming survival as end 
point of our study, we determined the most 
suitable cutoff value of CTCs for division of 
participants into favorable and unfavorable 
groups. Kaplan-Meier method was used to 
estimate the survival function of a series of 
baseline CTC values ranging from 1 to 10. After 
applying bonferroni correction factor, CTCs count 
5 was the only statistically significant factor that 
showed discriminative survival estimation (Table 
2). 
 
Univariate Cox proportional hazards regression 
analysis were done to determine significant 
prognostic factors related to progression free 
survival (PFS) and overall survival (OS). As a 
result of Univariate analysis only statistical 
significant parameters were included in 
multivariate cox proportional hazards analysis. 
PFS and OS were calculated from the date of 
baseline blood sample to date of death or were 
censored at last follow-up (confirmed clinical 
progression in case of PFS only). Considering p 
≤ 0.05 as statistically significant SPSS version 
20.0.0 was used for statistical analysis.  
 
 
Figure 1: Flow sheet of study methodology 
 
Table 2: Bonferroni method of correction to determine most significant CTC cutoff for survival 
 
Cutoff 
(CTC count) P-value p × 10 
Significant after 
correction (Yes/No) 
1 0.007 0.07 No 
2 0.006 0.06 No 
3 0.298 2.98 No 
4 0.088 0.88 No 
5 < 0.0001 < 0.001 Yes 
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One hundred and seventeen (117) patients 
diagnosed with NSCLC were consecutively 
included in current study. Patient`s 
demographics and characteristics are given in 
Table 3. Twenty four (24) patients were excluded 
from study after application of the exclusion 
criteria (five patients due to insufficient blood for 
analysis, eleven patients due to hepatic and 
renal dysfunctions, six patients due to concurrent 
malignancies and two patients were not willing to 
participate in study). Written consents were taken 
from all evaluable 93 patients. 
 
All the patients were subjected to CTCs 
enumeration before initiation of therapy. They 
were divided into five classes according to CTCs 
count (CTC ≤ 1, 2, 3, 4, ≥ 5). Association of 
CTCs count with patient`s characteristics and 
sites of metastasis can be seen in table 4 and 
table 5. High CTCs count is strongly associated 
with stage and histology of tumors (Fisher’s 
exact test p-value: 0.003 and .014 respectively). 
Significant association of CTC was also 
observed with bone and liver metastasis 
(Fisher’s exact test p-value: 0.021 and 0.013 
respectively). The number of metastasis sites 
were also significantly associated with high CTCs 
count (Fisher’s exact test p-value: 0.001). 
Performance score and smoking status were not 
associated with CTC (Fisher’s exact test p-value: 
0.295 and 0.211 respectively). 
 
Table 3: Participants demographics and clinical 
characteristics 
 
Characteristic Number (%) 


















































All the evaluable patients were divided into 
favorable (CTCs < 5) and unfavorable (CTCs ≥ 
5) groups according to the baseline CTC count. 
Out of the 93 patients, 82 (88 %) patients 
belonged to the favorable group while 11 (12 %) 
patients were included in the unfavorable group.  
During the study period, (45) 55 % of 82 patients 
from the favorable group and 8 (72 %) of 11 from 
the unfavorable group had tumor progression.  
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Table 4: Association of CTCs with clinical characteristics 
  








































4 8 26 .002 0 28 1 .003 0 29 6 .021 0 16 0 20 .045 42 3 0 0 .001 
CTCs 
≥ 2 
1 2 17 .003 4 15 3 .295 16 8 3 .211 10 1 4 7 .014 2 10 3 2 .001 
CTCs 
≥ 3 
0 1 13 .012 4 10 1 .291 10 7 1 .161 6 1 2 6 .013 0 8 3 2 .001 
CTCs 
≥ 4 
0 0 10 .021 7 7 1 .401 2 5 1 .257 6 0 2 4 .017 0 6 2 1 .003 
CTCs 
≥ 5 
0 0 11 .05 5 6 1 .211 0 4 1 .333 4 0 1 3 .041 0 6 2 1 .002 
*All the numbers given in tables are total number of patients, **Fisher`s exact test; PS: performance score, N: non-smoker, C: current smoker, F: former smoker, O: others, AC: 
adenocarcinoma, SCC: squamous cell carcinoma, UD: undifferentiated, CTC: circulating tumor cell 
 






























CTC < 1 7 32 .031 1 42 .002 1 52 .016 2 38 .021 0 36 .011 11 31 .011 
CTCs ≥ 2 2 19 .782 0 15 .031 4 14 .021 4 16 .417 4 15 .013 7 12 .887 
CTCs ≥ 3 2 12 .811 0 14 .033 3 7 .033 3 12 .871 2 11 .012 6 9 .431 
CTCs ≥ 4 2 9 .871 1 10 .167 3 4 .047 1 9 .891 2 6 .031 3 7 .977 
CTCs ≥ 5 1 7 .813 1 9 .235 2 3 .048 1 7 .987 1 5 .002 2 5 .989 
*All the numbers given in tables are total number of patients, **Fisher`s exact test 
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The risk factors of tumor progression were 
determined by univariate and multivariate 
survival analysis. Univariate analysis showed 
tumor stage (HR: 2.37), WHO PS (HR: 8.87) and 
treatment (HR: 0.09), which are significant 
factors for progression free survival (PFS) as 
shown in Table 6. 
 
All the evaluable patients were divided into 
favorable (CTCs < 5) and unfavorable (CTCs ≥ 
5) groups according to the baseline CTC count. 
Out of the 93 patients, 82 (88 %) patients 
belonged to the favorable group while 11 (12 %) 
patients were included in the unfavorable group.  
During the study period, (45) 55 % of 82 patients 
from the favorable group and 8 (72 %) of 11 from 
the unfavorable group had tumor progression. 
The risk factors of tumor progression were 
determined by univariate and multivariate 
survival analysis. Univariate analysis showed 
tumor stage (HR: 2.37), WHO PS (HR: 8.87) and 
treatment (HR: 0.09), which are significant 
factors for progression free survival (PFS) as 
shown in Table 6. 
 
All the significant predictors were subjected to 
multivariate cox proportion hazards regression 
analysis. CTCs ≥ 5 at baseline (HR: 4.23), CTCs 
≥ 5 at two time points (pretreatment and after 
one cycle of chemotherapy) (HR: 9.84), worse 
WHO PS (HR: 10.72) and severe tumor stage 
(HR: 1.96) were significant predictors for poor 
progression free survival as shown in Table 7. 
 
The median time to progression was 5.8 months 
(95 % CI, 5.32 to 6.43) in the favorable group 
and 2.2 months (95 % CI, 1.85 to 3.01) in the 
unfavorable groups. According to Univariate cox 
proportional analysis, hazards regression HR 
was 3.88 (p < .001) with 95% CI. 
 
At the time of analysis, 44 (54 %) of 82 patients 
in the favorable group and 3 (27 %) of 11 
patients in the unfavorable were alive. Significant 
predictors associated with overall survival (OS) 
are given in Table 8. The median OS was 7.3 
months (95 % CI, 6.51 to 7.92) for favorable 
group and 3.9 months (95 % CI, 1.99 to 5.13) for 
unfavorable group. According to Univariate cox 
proportional analysis, hazards regression HR 
was 4.86 (p < .001) with 95 % CI. Adrenal, bone 
and renal metastases were also significantly 
associated with overall survival in studied 
patients. 
 
CTC analysis after one cycle of standard 
chemotherapy was performed in patients having 
CTC counts ≥ 2. A dynamic change in CTC count 
was observed in all patients (n = 24) as shown in 
figure 3. Reduction in CTC count after one cycle 
of chemotherapy was observed in 19 (79 %) 
patients. Elevation in CTC counts were observed 
in 4 (17 %) patients while in one (4 %) patient 
CTC levels were constant after treatment. 
Patients in which reduction of CTC count was 
observed had significant (p < 0.01) progression 
free survival and overall survival as compared to 
those in which CTC count was increased. 
 








≥ 5 < 5 < .001 3.96 
Tumor stage IV IIIA & IIIB 0.018 2.37 
WHO PS 2 v 1 v 0 < .001 8.87 
Treatment Dual platinum therapy Single therapy < .001 0.09 
Liver metastasis Present Absent .038 2.04 
PFS: progression free survival, CTCs: circulating tumor cells, WHO PS: World Health Organization performance 
status, HR: hazard ratio 
 




Favorable group Unfavorable Group P–value Progression free 
survival risk (HR) 
Baseline CTCs count ≥ 5 < 5 < .001 4.23 
CTC at two time points ≥ 5 at either time 
point 
< 5 at both before and 
after treatment 
< .001 9.84 
Tumor stage IV IIIA & IIIB .022 1.96 
WHO PS 2 v 1 v 0 < .001 10.72 
PFS: progression free survival, CTCs: circulating tumor cells, WHO PS: World Health Organization performance 
status, HR: hazard ratio 
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Unfavorable group Favorable Group 
 




≥ 5 < 5 < .001 5.24 
Tumor stage IV IIIA & IIIB .044 1.98 
WHO PS 2 v 1 v 0 .008 4.21 
Treatment Dual Platinum therapy Single therapy .031 0.15 
Liver metastasis Present Absent .020 2.35 
Bone metastasis Present Absent .041 1.97 
Adrenal metastasis Present Absent .033 2.13 
Clinical 
Characteristics 
Unfavorable group Favorable Group 
 




≥ 5  < .001 6.38 
CTC at two time 
points 
≥ 5 at either time point   < .001 13.64 
Adrenal metastasis Present Absent .031 2.13 
WHO PS 2 v 1 v 0 .008 11.89 
PFS: progression free survival, CTCs: circulating tumor cells, WHO PS: World Health Organization performance 
status, HR: hazard ratio 
 
Out of 23 patients with no CTCs at baseline, one 
patient had CTCs after chemotherapy. This 
patient had stage IV disease and died at 3.1 
months. Progression free survival and overall 
survival was better in patients having no CTCs at 
baseline as compared to those having CTCs at 
baseline (p < 0.001). Progression free survival 
after one cycle of treatment in favorable and 
unfavorable groups was 7.1 months and 2.7 
months respectively. On the other hand, overall 
survival after one cycle of treatment in favorable 
and unfavorable groups was 7.9 months and 4.1 
months respectively. 
 
Figure 3: Change in CTCs count before and after one cycle of chemotherapy in CTC positive (CTCs count ≥ 2) 
patients (n = 24) [Each line represents one patients, these are 24 lines representing 24 patients] 
 
Bi et al 
Trop J Pharm Res, September 2015; 14(9): 1730  
 
 Significant reduction (p < 0.01) in CTCs count 
was observed in patients having high (> 80) 
values of CTCs as compared those having low (< 




Primary lung cancer is one of the leading causes 
of cancer-related deaths in industrialized regions. 
Distant metastases can be present in 
approximately 40 % of patients that may result in 
fatal cases. These metastases may develop 
during or after chemotherapy and can be 
detected by current diagnostic modalities. 
Circulating tumor cells in peripheral blood may 
cause development of clinically apparent distant 
metastases. Therefore detection of such 
circulating cells (CTCs) may improve diagnosis 
and therapy in patients suffering from primary 
lung cancer [17]. 
 
The potential advantage of a CTC test may be its 
ability to predict the presence of a micro-
metastasis that is undetectable with routine 
diagnostic modalities. Prognostic significance in 
different tumors has been well established [8-10]. 
Moreover few reports have demonstrated the 
clinical significance of CTCs with small cell lung 
cancer (SCLC) [11] and its prognostics 
significance has also been studied in NSCL [6]. 
But there is still scarcity of data showing 
importance of CTCs enumeration during the 
treatment of NSCLC. 
 
We performed a prospective single center study 
to evaluate the prognostic importance of CTCs in 
NSCLC. All the studied participants with 
metastatic disease had ≥ 2 CTCs. A significant (p 
< .001) difference in progression free survival 
(PFS) and overall survival (OS) were observed 
between the favorable and unfavorable groups. 
Similarly patients with ≥ 5 CTCs had worse 
prognosis after chemotherapy as compared to 
favorable group`s participants. We found that an 
increasing number of CTCs is directly 
proportional to a worse clinical picture of non-
small cell lung cancer i.e. high WHO-PS and 
severe tumor stage. CTCs count were s 
significantly reduced after one cycle of 
chemotherapy and this reduction was more 
significant in patients with CTCs count > 80. We 
found several patients without CTC (negative 
CTC) even in severe stages of NSCLC. It might 
be due to formation of very small microemboli by 
CTCs that were not detected by the CellSearch 
system. 
 
For CTCs enumeration, we used the CellSearch 
system that has been extensively validated in 
patients with metastatic carcinomas. We used 5 
CTCs as a cutoff value because this value has 
previously been reported as prognostic in 
different tumors in several large multicenter trials 
[8,11].  
 
The findings of our studies are consistent with 
Krebs et al [6]. The median progression free 
survival in Kreb`s study among two studied 
cohorts (< 5 CTCs vs ≥ 5 CTCs) was 6.8 months 
and 2.4 months respectively. Similarly overall 
survival was 8.1 months and 4.3 months 
respectively. Though number of patients is 
insignificantly less in our study (101 vs 93) but 
the number of patients for who a post-treatment 
blood sample was obtained was high in our study 
(18 vs 24). Our findings are comparable with 
Krebs study data. 
 
Limitations of the study 
 
The major limitations of the current study were 
that the study population was small and the study 
was performed at a single institution. In addition, 
the study population included patients treated by 
chemoradiotherapy as well as patients who were 
treated by chemotherapy alone. Since the 
purposes of chemotherapy and 
chemoradiotherapy are different, separate 
derivation studies are required to determine the 




The findings of this study support the fact that 
CTCs are associated with tumor stage, 
metastasis and WHO PS. The presence of CTCs 
results in poor prognosis and higher levels of 
CTCs are related to both poor progression-free 
survival and overall survival. CTC enumeration 
may help in the selection of therapy, evaluation 
of patients to ascertain whether they are 
benefiting from treatment or not, and the decision 
to administer adjuvant therapy. Larger 
prospective clinical cohorts are required for the 




The authors are grateful for the support received 
from the outpatient oncology clinic of Qiqihar 
Medical University Hospital and the provision of 




1. Brambilla E, Travis WD. Lung cancer. In: World Cancer 
Report, Stewart BW, Wild CP (Eds), World Health 
Organization, Lyon 2014 
Bi et al 
Trop J Pharm Res, September 2015; 14(9): 1731  
 
2. Wang YC, Wei LJ, Liu JT, Li SX, Wang QS. Comparison 
of Cancer Incidence between China and the USA. 
Cancer Biol Med 2012; 9(2): 128- 132. 
3. Tanaka FYK, Hasegawa S. Circulating tumor cells 
(CTCs) in lung cancer: current status and future 
perspectives. Lung Cancer: Targets and Therapy 
2010; 1: 77 - 84. 
4. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome 
PA, Rami-Porta R and International Association for 
the Study of Lung Cancer International Staging 
Committee. (2007). The IASLC Lung Cancer Staging 
Project: Proposals for the revision of the TNM stage 
groupings in the forthcoming (7th) edition of the TNM 
Classification of malignant tumours. J Thorac Oncol 
2007; 2(8): 706-714. 
5. Huang J, Wang K, Xu J, Huang J, Zhang T. Prognostic 
Significance of Circulating Tumor Cells in Non-Small-
Cell Lung Cancer Patients: A Meta-Analysis. PloS 
One 2013; 8(11): e78070. 
6. Krebs MG, Sloane R, Priest L, Lancashire L, Hou JM, 
Greystoke A, Ward TH, Ferraldeschi R, Hughes A, 
Glen C et al. Evaluation and prognostic significance 
of circulating tumor cells in patients with non–small-
cell lung cancer. J Clin Oncol 2011; 29(12): 1556 - 
1563. 
7. Boshuizen R, Kuhn P, Van Den Heuvel M. Circulating 
tumor cells in non-small cell lung carcinoma. Journal 
of thoracic disease 2012; 4(5): 456. 
8. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, 
Miller MC. Circulating tumor cells, disease 
progression, and survival in metastatic breast cancer. 
New Eng J Med 2004; 351(8): 781-791. 
9. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath 
KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller 
MC et al. Relationship of circulating tumor cells to 
tumor response, progression-free survival, and 
overall survival in patients with metastatic colorectal 
cancer. J Clin Oncol 2008; 26(19): 3213 - 3221. 
10. De Bono JS, Scher HI, Montgomery RB, Parker C, Miller 
MC, Tissing H, Doyle GV, Terstappen LWWM, Pienta 
KJ, Raghavan D Circulating tumor cells predict 
survival benefit from treatment in metastatic 
castration-resistant prostate cancer. Clin Cancer Res 
2008; 14(19): 6302 - 6309. 
11. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward 
T, Board R, Amer E, Hughes S, Krebs M, Hughes A 
et al. Evaluation of circulating tumor cells and 
serological cell death biomarkers in small cell lung 
cancer patients undergoing chemotherapy. Am J 
Pathol 2009; 175(2): 808 - 816. 
12. Wendel M, Bazhenova L, Boshuizen R, Kolatkar A, 
Honnatti M, Cho EH, Marrinuchii D, Sandhu A, 
Perricone A, Thistlethwaite P et al. Fluid biopsy for 
circulating tumor cell identification in patients with 
early-and late-stage non-small cell lung cancer: a 
glimpse into lung cancer biology. Physical Biol 2012; 
9(1): 016005. 
13. Das M, Riess JW, Frankel P, Schwartz E, Bennis R, 
Hsieh HB et al. ERCC1 expression in circulating 
tumor cells (CTCs) using a novel detection platform 
correlates with progression-free survival (PFS) in 
patients with metastatic non-small-cell lung cancer 
(NSCLC) receiving platinum chemotherapy. Lung 
Cancer 2012; 77(2): 421 - 426. 
14. Devriese LA, Bosma AJ, Van De Heuvel MM, 
Heemsbergen W, Voest EE, Schellens JHM. 
Circulating tumor cell detection in advanced non-
small cell lung cancer patients by multi-marker QPCR 
analysis. Lung Cancer 2012; 75(2): 242 - 247. 
15. Hofman V, Bonnetaud C, Ilie MI, Vielh P, Vignaud, JM, 
Fléjou JF, Hofman P. Preoperative circulating tumor 
cell detection using the isolation by size of epithelial 
tumor cell method for patients with lung cancer is a 
new prognostic biomarker. Clin Cancer Res 2011; 
17(4): 827 - 835. 
16. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, 
Rao C, Terstappen LW. Tumor cells circulate in the 
peripheral blood of all major carcinomas but not in 
healthy subjects or patients with nonmalignant 
diseases. Clin Cancer Res 2004; 10(20): 6897 - 
6904. 
17. Tanaka FYK, Yoneda K, Hasegawa S. Circulating tumor 
cells (CTCs) in lung cancer: current status and future 
perspectives. Lung Cancer: Targets and Therapy 
2010; 1: 77 - 84. 
 
